Biomarkers based on alterations in molecular and biochemical parameters may be useful in chemical risk assessment for establishing the presence of an exposure, ranking relative risks among exposed individuals, and estimating risks at low levels of exposure. Because it is unlikely that the relation between toxic responses and the degree of alteration in the biomarker is equivalent at all doses, quantification of risks at low levels is not necessarily more accurate using these biomarkers for extrapolation. The application of response biomarkers for risk evaluation at low levels of exposure is discussed in relation to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a compound that causes induction of cytochromes CYP1 Al and CYP1A2 in liver and other tissues. CYP1A1 induction in liver increases monotonically with TCDD dosage; however, several of the dose-response curves for hepatic effects of TCDD are U-shaped. The U-shaped dose-response curve for hepatic tumor promotion appears to result because the integrated toxicologic response depends on multiple underlying processes-mitosuppression, toxicity, and cell proliferation-each of which has a different dose-response relationship with respect to TCDD. Although dose-response relationships for the biomarkers are not expected to duplicate the complex shapes seen with the integrated responses, measurements and pharmacodynamic modeling of the changes in these molecular and biochemical parameters can still be useful for obtaining an upperbound risk estimate at low levels of exposure. Environ Health Perspect 106 (Suppl 1:349-355 (1998). http.//ehpnetl.niehs.nih.gov/docs/1998/Suppl-1/349-355andersen/abstract.html
Introduction
Epidemiologic studies in human populations are expected to be more relevant for human risk assessments than the results of animal toxicity studies. However, because of confounding factors related to concurrent exposures to other chemicals, differences in individual lifestyles, difficulties in accurately reconstructing exposures, and the small sizes of most cohorts, few epidemiologic studies provide results that unambiguously determine risks to humans at low levels of exposure. Thus, most contemporary risk assessments are based on results from animal studies, in which it is possible to control the exposure conditions and expose animals to high doses of overtly toxic compounds.
In these cases, accurate estimation of risks to human health posed by low-level exposure to potentially toxic compounds requires knowledge of the dose-response relationship over a broad range of exposures in the animal species. Unfortunately, dose-response curves that define risks in animals at low response rates are almost nonexistent and in some cases may be impossible to obtain. For Abbreviations used: Ah, aryl hydrocarbon; arnt, aryl hydrocarbon nuclear transferase; DEN, diethylnitrosamine; DREs, dioxin response elements; GST, glutathione S-transferase; PCB, polychlorinated biphenyl; PCDD, polychlorinated dibenzo-p-dioxin; PH, partial hepatectomy; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin. above background response rates. These studies only infrequently resolve differences of response in the 1 in 20 to 1 in 100 range. When evaluating impaired function such as reproductive competence, the natural variability in a healthy population of measures of effect such as numbers of live births per litter greatly restrict accurate assessment of low-level response rates related to chemical exposures.
It may be possible to extend doseresponse curves to lower levels of exposure based on theoretical knowledge of the mechanisms of toxicity by using so-called biologically based models or by measuring precursor biochemical or molecular events directly involved in the sequence of events leading to toxicity states. Proposed revised carcinogen risk assessment guidelines (1) discuss the use of these precursor events to extend the dose-response curve to low levels of exposure and the role of biologically based models in cancer risk assessment. Precursor events should be causally related to toxicity to be useful in risk assessment. A precursor response linked mechanistically to toxicity is equivalent to a biomarker of response.
Biomarkers in Risk Assessment
Biomarkers are used to indicate that an individual has been exposed to a toxic chemical (exposure biomarkers) or that an individual is at some risk of toxicity because of the exposure (response biomarkers). Biomarkers of exposure include the presence of the compound or a specific metabolite in blood or tissues or the presence of macromolecular reaction products such as hemoglobin adducts, which are not related causally to any adverse outcome. Blood cholinesterase inhibition by organophosphate insecticides is considered a biomarker of exposure because the inhibition of this enzymatic activity is not believed to be involved directly in the neurotoxicity of these compounds. These 
Response Markers with TCDD
TCDD is a member of the class of polychlorinated dibenzo-p-dioxins (PCDDs). Many of these PCDDs, especially those with lateral chlorine substituents, produce a characteristic constellation of biologic effects in experimental animals; these effects indude liver cancer in female rats (2, 3) , teratogenicity (4) and immunotoxicity in mice (5) , and reproductive/developmental effects in adult male and female rats exposed in utero (6, 7) . Cancer is a relatively high dose effect compared to these other responses.
TCDD Biomarkers
In addition to these overt toxic effects, TCDD also produces changes at the molecular and biochemical levels, including increases in the concentrations of a number of enzymes involved in cellular metabolism. The most extensively studied effect is the induction of two cytochrome P450 enzymes, CYPlAl and CYP1A2, in multiple animal species. The (12) evaluated the ability of TCDD to promote growth of altered enzyme foci in livers of female rats initiated by a regimen of two-thirds partial hepatectomy (PH) followed by a dose of 10 mg diethylnitrosamine (DEN) per kg body weight. TCDD was a potent promoter in this study, causing an increase in the number of foci per volume and in the amount of the liver occupied by foci at daily doses of 100 ng TCDD/kg. The dose-response curve for these effects appeared to be U-shaped ( Figure 1) . Van Bergelen et al. (13) found that TCDD treatment increased the concentrations of porphyrins in the liver and that this increase correlated well with the induction of CYP1A2. Mechanistically, this correlation may arise because the metabolism of uroporphyrinogen III to uroporphyrin III is catalyzed by CYP1A2 (14) . TCDD also increases the proliferation rate of hepatocytes and induces toxicity, defined as cytoplasmic vacuolation, fatty changes, bile duct hyperplasia, and pigment in Kupfer cells (15) . Stinchcombe et al. (16) found that apoptotic rates of the cells in altered foci staining positively for glutathione S-transferase (GST) produced by TCDD treatment were much lower than the apoptotic rates measured in these foci in the absence of TCDD. Any of these various (12) . The doses used correspond to the daily doses used in the original cancer bioassay (2). In the original bioassay (2) the incidence of cancer at the three doses-0.001, 0.01, and 0.1 pg/kg/day-were 1/86, 0/50, 2/50, and 11/49, respectively. In the Pitot et al. study ( 12) the control rats were sacrificed at 8 months, while the treated rats were sacrificed at 6 months (36). These differences diminish the U-shaped behavior for volume occupied by AHF; they are not expected to affect the overall shape of the curve for AHF numbers in the liver.
processes may be regarded as precursor steps to the development of liver tumors.
Specificity and Sensitivity
Two important concepts in evaluating the utility of any particular biomarker are whether the biomarker can be associated uniquely with a specific exposure (specificity) and whether it is clearly elevated at even low levels of exposure (sensitivity). (20) (21) (22) (23) (24) . These initial CYP1A family induction models did not consider heterogeneous induction in evaluating the dose response for this molecular marker of the effects ofTCDD on the liver. These earlier models were successful in explaining the induction averaged over the whole liver but required alteration to simultaneously describe the nonlinear induction of CYPlAI mRNA by TCDD (17) .
Models ofRegional Induction
These pharmacokinetic and gene induction models recently were extended to consider regional effects together with the observation of the sharp boundary between induced and noninduced regions (25, 26 Figure 2 . A schematic representation of the surfaces of hexagonal acinar structures within the liver in the geometric liver model used to predict regional induction characteristics with TCDD. The most recent physiologically based pharmacokinetic (PBPK) models for TCDD subdivide the liver acinus into five compartments based on concentric regions within the acinus (25, 26) . This geometric model (Al allows prediction of regional induction (1) by assuming different binding characteristics of TCDD with DNA response elements in each region. Estimates of total induction in a region are estimated and compared to maximally induced levels. The proportion induction is then used to calculate a color intensity for the region (B). To obtain sharp boundaries with some fully induced regions (the two centrilobular zones) and other noninduced regions (the two periportal zones), the Hill coefficients in the induction equations in the PBPK models must be 4 
Mechanisms ofPromotion and Carcinogenicity
Two proposals have been made to account for the potency of TCDD as a tumor promoter. Portier et al. (29) and Moolgavkar et al. (30) developed models of promotion in which DEN treatment produced a single type of mutated cell. All clones observed at each dose of TCDD were believed to be derived from that single cell type. Based on this biologic structure for the nature of the mutated cell population, the initiationpromotion data were consistent with a model in which TCDD acted as an initiator to increase the production of mutated cells over time during the study. This conclusion is difficult to reconcile with the fact that TCDD increases with increasing concentrations of TCDD. At the high exposure concentrations in the initiation-promotion studies, the observed clones are derived primarily from these B cells. This two-cell model is consistent with the observed U-shaped dose-response curves, explains TCDD promotion without assuming a mutational component to the formation of the clones over time, and is consistent with a mitoinhibitory action of TCDD on normal cells that is absent in the B-cell clones (34) .
Dose Dependencies of Response Mechanisms
The data on hepatic effects of TCDD are consistent with three distinct ranges of behavior (Table 1) . Lower doses (1-5 ng/kg/day in rats) affect a small portion of the hepatocytes (up to about 10%) and appear to have little effect on either cell proliferation rates or toxicity. There may be limited mitosuppression in this region (Figure 3 (35) , the ongoing toxicity with TCDD in the face of the homeostatic, mitoinhibited environment sets the stage for a higher probability of conversion of cells with growth regulatory lesions to more aggressive carcinoma.
Several lines of evidence support U-shaped dose-response curves for hepatic effects of TCDD, including initiation/ promotion (12), carcinogenicity (2), and cell labeling (15) . The downward sloping portion of these curves appears to be in the range where mitosuppression occurs. This mitoinhibition appears to protect the liver from carcinoma production. It would be misleading, however, to call this low-dose protection.
The overall U-shaped curve appears to be associated with regions of the dose-response regime in which different effects of dioxin predominate over others. At high doses the combination of proliferation, toxicity, and mitoinhibition acts to enhance carcinogenicity. At lower doses mitoinhibition, acting in the absence of toxicity and proliferative responses, appears to moderate cell proliferation and reduce the incidence of foci production and tumors relative to those in controls. This region is not a dose region where all effects of TCDD are expected to be beneficial. It is a region in which the mitoinhibition in liver predominates over other effects. In other tissues the TCDD-related effects associated with these altered cell growth characteristics may be associated with other toxic effects. One caution from this evaluation of the possibility of U-shaped curves with TCDD relates to the definitions of both hormesis and low levels of exposure. Low levels of exposure, in this context, simply refer to levels below those that have overt increases in toxic responses. The dose that causes a low-level response in one tissue may be associated with much higher levels of response in a second tissue. Hormesis is an empirical definition based on observing complex dose-response curves for specific toxic responses. When we realize that the pathogenicities of most toxic responses are composites of multiple effects of the chemical on the organ system, it is easy to see that complex curves may arise from differential dose-response relationships for the contributing mechanisms of pathogenesis.
Summary
Molecular and biochemical biomarkers of response are qualitatively useful in assessing whether risk can be attributed to an exposure by assessing whether an increase in the biomarker has occurred. Among groups of exposed individuals, the magnitude of a biomarker in any one individual can be used to broadly categorize exposure and to rank the degree of risk for various individuals. However, it is difficult to estimate lowdose risks based solely on the intensity of biochemical and molecular markers of response. Most biomarkers are not proportionally related to the toxic response, and the underlying mechanisms of toxicity contributing to pathogenesis are themselves complexly related to dose. Therefore, it is unlikely that simple relationships will emerge between early molecular and biochemical parameters and toxic responses at low levels of exposure.
Biochemical and molecular parameters that are specific and sensitive may be useful for identifying doses below which increases in biomarker are not statistically significant. Experimental measurements alone cannot unequivocally establish a total lack of response because of the statistical power of the test systems. Biologically based pharmacodynamic models such as that for regional and cell-specific induction with TCDD have the potential to provide characterization of the functional relationships between dose and the biomarker and may increase our confidence in extending the predictions of the dose-response relationship for the biomarker to lower doses based on mechanistic considerations. In contrast to toxicity processes, molecular responses such as CYPIA family induction are simpler and depend on fewer biologic factors than toxic and carcinogenic sequelae. Therefore, these models of low-level increases in biomarkers are more likely to be testable by experimental studies than pharmacodynamic models of toxic responses. Despite difficulties in equating biomarker concentrations with specific degrees of risk, estimation of low-level risks based on these biomarkers is likely to be important in placing an upper bound on risk if it is assumed that a direct relation exists between the biomarker and toxicity.
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